SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire & inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is trending strongly as its staking program sees significant adoption, with a substantial portion of tokens now locked, which the community views as a bullish indicator. Holders are rallying around its unique narrative as a 'pure belief asset' offering an alternative to traditional retirement plans, fueling widespread conviction.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after securing FDA approval for NEREUS, marking the first new motion sickness treatment in decades. The community is highly focused on the drug's significant potential beyond motion sickness, particularly its ability to address nausea associated with GLP-1 weight loss medications, which could unlock a massive market. Investors are actively discussing whether the current valuation fully reflects this pivotal regulatory success and the company's broader pipeline.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology (AFJK) is currently experiencing extreme price swings and frequent trading halts, sparking active community discussion around its highly speculative nature as a "casino play." Many traders are focusing on its ultra-low float and high borrow rates, anticipating potential short squeezes, while others caution against a perceived "Chinese mafia pump" pattern often seen in similar volatile Chinese IPOs.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is generating significant buzz in the trading community, largely driven by its exceptionally low float and high insider ownership. Many view it as the next potential 'squeeze' play, drawing strong comparisons to recent low-float SPACs like AFJK and ASPC which saw substantial upward movement. This unique structural setup fuels active discussion about its potential for rapid price action.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing high volatility as investors await an overdue FDA decision on Relacorilant for Cushing's syndrome, a key PDUFA date that passed without official news. This has ignited intense community debate, with some highlighting strong GRACE trial data and the broader pipeline, while others express concern that the delay may indicate a Complete Response Letter amidst notable trading volume and market speculation.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co

Alpha Capital Acquisition Co. is generating significant buzz due to its extremely low public float and status as a SPAC, fueling speculation about a potential parabolic surge. The community is actively discussing its 'time bomb' setup and drawing comparisons to other volatile low-float stocks, with many anticipating a short squeeze amid frequent trading halts.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amid analyst caution on its revenue outlook, largely attributed to crypto market weakness. Simultaneously, its holiday "free gift" giveaways are sparking considerable community debate, with users expressing both appreciation for small crypto rewards and frustration over app glitches. Conversations also revolve around its sensitivity to Bitcoin's price and its future as a broad fintech platform.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending following an eight-figure contract award to provide spacecraft docking systems for The Exploration Company's European Nyx capsule. This news, coupled with the company's significant short interest and its strategic position in the burgeoning space infrastructure and defense sectors, is fueling community speculation about a potential short squeeze and a substantial revaluation.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors eagerly await an FDA decision on its AXS-05 supplemental NDA for Alzheimer's disease agitation, viewed as a significant catalyst for an underserved market. This anticipation is fueled by consistently strong and growing prescription numbers for Auvelity in major depressive disorder, reflecting robust commercial execution. The company's expanding CNS pipeline and positive analyst sentiment continue to reinforce its perceived long-term value within the biopharmaceutical sector.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

ProShares Short Bitcoin Strategy ETF ($BITI) is a focal point of market discussion as bearish sentiment on Bitcoin gains traction, with many anticipating a significant cryptocurrency pullback. The community is actively debating using inverse ETFs like BITI to either capitalize on or hedge against a potential Bitcoin correction, citing concerns over its speculative nature and "bubble" warnings from prominent investors. This reflects a prevailing view among some that Bitcoin's recent rally faces considerable downside risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totaling 101,167 shares, a growth of 105.6% from...

Oculis (NASDAQ:OCS) Shares Down 4.3% - Time to Sell?

Oculis (NASDAQ:OCS) Trading Down 4.3% - Should You Sell...

Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade

Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade...

Oculis (NASDAQ:OCS) Price Target Raised to $40.00 at Stifel Nicolaus

Stifel Nicolaus boosted their target price on shares of Oculis from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday...

Oculis (NASDAQ:OCS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on Oculis in a research report on Friday. They issued an "overweight" rating and a $38.00 target price on the stock...

Oculis Holding AG (NASDAQ:OCS) Receives Consensus Rating of "Moderate Buy" from Analysts

Oculis Holding AG (NASDAQ:OCS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat reports. One analyst has...

Oculis (NASDAQ:OCS) Trading Down 6% - Should You Sell?

Oculis (NASDAQ:OCS) Trading Down 6% - Time to Sell...

Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's  What You Should Know

The consensus price target hints at a 106% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Oculis (NASDAQ:OCS) Trading 7% Higher - Here's What Happened

Oculis (NASDAQ:OCS) Shares Up 7% - Here's What Happened...

Lifesci Capital Forecasts Oculis FY2025 Earnings

Oculis Holding AG (NASDAQ:OCS - Free Report) - Research analysts at Lifesci Capital issued their FY2025 earnings per share estimates for shares of Oculis in a research note issued to investors on...

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

OCS
Oculis Holding AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCS News

OCSOculis Holding AG